Moldova Pharmaceuticals and Healthcare Report Q2 2016

82 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: Moldova’s pharmaceutical market presents very limited opportunities for multinational
drugmakers, in comparison to its neighbours in Eastern Europe. The country’s small total market size and
its reliance on out-of-pocket payments highlight the challenges it poses. Moldova’s economic outlook, which
is defined by its relations with Russia and the EU, will play a significant role in how the market grows over
the coming years.
Headline Expenditure Projections
? Pharmaceuticals: MDL5.83bn (USD310mn) in 2015 to MDL6.23bn (USD322mn) in 2016; 6.8% in
local currency terms and 4.1% in US dollar terms.
? Healthcare: MDL13.86bn (USD736mn) in 2015 to MDL14.80bn (USD765mn) in 2015; +6.8% in local
currency terms and 4.0% in US dollar terms.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Moldova 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Moldova 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Moldova 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Moldova 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Moldova 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Moldova 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Moldova 2012-2020) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Moldova 2012-2020) 24
OTC Drug Market Forecast | 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Moldova 2012-2020) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (Moldova 2014-2020) 29
Table: Pharmaceutical Trade Data And Forecasts local currency (Moldova 2014-2020) 30
Industry Risk Reward Index 31
Central And Eastern Europe Risk/Reward Index 31
Moldova Risk/Reward Index 37
Rewards 37
Risks 38
Regulatory Review 39
Intellectual Property Issues 41
Pricing Regime 42
Reimbursement Regime 43
Market Overview 45
Healthcare Sector 46
Research And Development 49
Clinical Trials 50
Epidemiology 51
Competitive Landscape 54
Research-Based Industry 54
Table: Multinational Market Activity 56
Pharmaceutical Distribution 56
Pharmaceutical Retail Sector 57
Company Profile 59
Gedeon Richter 59
GlaxoSmithKline 61
Novartis (Sandoz) 63
Pfizer 65
Sanofi 67
Top Pharm 69
Demographic Forecast 71
Table: Population Headline Indicators (Moldova 1990-2025) 72
Table: Key Population Ratios (Moldova 1990-2025) 72
Table: Urban/Rural Population & Life Expectancy (Moldova 1990-2025) 73
Table: Population By Age Group (Moldova 1990-2025) 73
Table: Population By Age Group % (Moldova 1990-2025) 74
Glossary 76
Methodology 78
Pharmaceutical Expenditure Forecast Model 78
Healthcare Expenditure Forecast Model 78
Notes On Methodology 79
Risk/Reward Index Methodology 80
Index Overview 81
Table: Pharmaceutical Risk/Reward Index Indicators 81
Indicator Weightings 82

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Moldova 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Moldova 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Moldova 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Moldova 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Moldova 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Moldova 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Moldova 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Moldova 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Moldova 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Moldova 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Moldova 2014-2020)
Table: Multinational Market Activity
Table: Population Headline Indicators (Moldova 1990-2025)
Table: Key Population Ratios (Moldova 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Moldova 1990-2025)
Table: Population By Age Group (Moldova 1990-2025)
Table: Population By Age Group % (Moldova 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Moldova Pharmaceuticals and Healthcare Report Q1 2016BMI View: The Moldovan pharmaceutical market represents a small opportunity within Eastern Europe, given the total market size and reliance of the market on out-of-pocket payments. Moldova's economic outlook, which is defined by its relations with Russia and the EU, will play a significant role in how the market grows over the coming years. Headline Expenditure Projections ? Pharmaceuticals: MDL5.53bn (USD394mn) in 2014 to MDL5.83bn (USD333mn) in 2015; +5.5% in local currency terms […]
  • Moldova Pharmaceuticals and Healthcare Report Q2 2015BMI View: While short-term prospects for the Moldovan pharmaceutical market present limited opportunities for investors, long term opportunities in the region show great potential. With Moldovan relationships strengthening between China and Europe, the Pharmaceutical market is expected to grow as a result in the long term. Moldova's economic outlook will continue to have a significant impact on the pharmaceutical market's growth trajectory over the forecast period. Headline […]
  • Nicaragua Pharmaceuticals and Healthcare Report Q2 2016BMI View: Access to affordable medicine will continue to be challenging for the majority of Nicaraguans in the coming years. Limited healthcare funding, low per capita pharmaceutical expenditure, a small and unregulated drug market and the socio-cultural preference for traditional medicines will present limited opportunities for innovative drugmakers. Headline Expenditure Projections Pharmaceuticals: NIO10.93bn (USDb401mn) in 2015 to NIO11.42bn (USD399mn) in 2016; +4.3% in local […]
  • Russia Pharmaceuticals and Healthcare Report Q2 2016BMI View: Russia's healthcare market is in a precarious position due to a severe lack of funding and an escalating burden of disease. The country's economic recession will see further pressure placed on the population for provision of care. Amendments to Russia's pharmaceutical legislation will, however, favour domestically-produced medicines over foreign drugmakers and multinational drugmakers will be pressured to establish a domestic manufacturing presence to comply to related new […]
  • Hungary Pharmaceuticals and Healthcare Report Q2 2016BMI View: The Hungarian healthcare sector will continue to face challenges which will limit the country's attractiveness to multinational pharmaceutical firms. Low wages, a rising disease burden and the migrant crisis have caused the healthcare system to be labelled as in a critical condition. Headline Expenditure Projections ? Pharmaceuticals: HUF660.80bn (USD2.37bn) in 2015 to HUF668.00bn (USD2.28bn) in 2016; +1.1% in local currency terms and -3.5% in US dollar terms. Forecast […]